IMMUNOME INC (IMNM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for IMNM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IMNM | Director | 58 | ["Lead independent director of the Board since October 2023","Member of the board of directors of Research Bridge Partners since January 2017","President and Chief Executive Officer of Research Bridge Partners from January 2017 until January 2024","Director of the Austin Technology Incubator from 2006 to 2016","Worked at McKinsey & Company from 1996 to 2006","Board member of Courage Therapeutics, Inc. since May 2025","Board member of Tetricus Labs from October 2022 until January 2026","B.A. from Stanford University","M.A. and J.D. from the University of Chicago","Extensive investment and business experience in life sciences and biotechnology sectors"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
Biography sourced from the proxy statement filing.
Isaac Barchas, J.D. has served as the lead independent director of the Board since October 2023. Mr. Barchas has served as a member of the board of directors of Research Bridge Partners, a biotechnology accelerator, since January 2017, and previously served as its President and Chief Executive Officer from January 2017 until January 2024. Mr. Barchas also previously served as Director of the Austin Technology Incubator from 2006 to 2016. Mr. Barchas also worked at McKinsey & Company from 1996 to 2006. Mr. Barchas has served on the board of directors of Courage Therapeutics, Inc., a private biotechnology company, since May 2025, and previously served on the board of Tetricus Labs, a private technology company, from October 2022 until January 2026. Mr. Barchas received his B.A. from Stanford University and his M.A. and J.D. from the University of Chicago. The Nominating Committee and the Board believe that Mr. Barchas is qualified to serve on the Board due to his extensive investment and business experience in the life sciences and biotechnology sectors.